Welcome to our dedicated page for AGENUS SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AGENUS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AGENUS's regulatory disclosures and financial reporting.
Agenus Inc. has completed the sale of substantially all assets of its manufacturing operations, primarily run through Agenus West, to Zydus for cash consideration of $75.0 million, less certain reimbursable expenses and other closing payments, with the transaction closing on January 15, 2026. The disposition is treated as a significant business disposition, and Agenus has filed unaudited pro forma condensed consolidated financial statements as of September 30, 2025 and for earlier periods.
At the same time, a previously announced License Agreement with Zydus Lifesciences Limited became effective, granting Zydus an exclusive license in India and Sri Lanka to develop, manufacture, and commercialize products based on Agenus’ proprietary BOT/BAL cancer immunotherapy drug product. Agenus also closed a Securities Purchase Agreement with Zynext Ventures USA LLC, under which Zynext purchased 2,133,333 shares of Agenus common stock for approximately $16.0 million, or $7.50 per share, in an unregistered equity sale.
Agenus Inc. reported leadership changes in its finance function. Effective January 8, 2026, the Board appointed Chairman and Chief Executive Officer Dr. Garo Armen, age 72, to also serve as interim Chief Financial Officer and Principal Financial Officer. There were no new or modified compensation arrangements tied to this added role, and he continues to receive his base salary and any potential bonus payments in Agenus stock rather than cash.
Also effective January 8, 2026, the Board appointed Austin Charette, age 37, currently Senior Director of Financial Reporting and Compliance, as Principal Accounting Officer. He has been with Agenus since 2017 in various financial reporting and compliance roles, following prior experience at Deloitte & Touche LLP. The company states there are no new compensation arrangements or related-party relationships connected to either appointment.
Agenus Inc. Chairman and CEO Garo H. Armen, who also serves as a director, reported receiving 3,780 shares of Agenus common stock on January 9, 2026. According to the disclosure, at his request and with compensation committee approval, his salary for the pay period ending that date is being paid in stock instead of cash, with these shares fully vested on issuance and valued at the closing price of $3.91 per share on January 9, 2026.
After this stock-salary grant, Dr. Armen directly holds 311,123 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he is trustee or general partner and has a pecuniary interest in only a portion of certain shares.
Agenus Inc. entered into an amendment and release agreement with Ligand Pharmaceuticals related to a previously disclosed purchase and sale agreement and warrant. Under this amendment, Ligand agreed to release liens it holds on certain Agenus assets. In return, the exercise price of Ligand’s warrant was reduced from $17.30 per share to $7.50 per share, changing the economic terms of that warrant for future exercises.
AGENUS INC reported an insider equity transaction by its Chairman and Chief Executive Officer, Garo H. Armen, who is also a director. On December 26, 2025, Dr. Armen received 4,942 shares of common stock as payment of his salary for the pay period ending that day, instead of cash. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, at a reference price of $3.31 per share, which was the closing price of the common stock on that date.
Following this transaction, Dr. Armen beneficially owned 307,343 shares of Agenus common stock directly. He also held shares indirectly, including amounts in his IRA accounts and interests in entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. reported that Chairman and Chief Executive Officer Garo H. Armen received 4,316 shares of common stock on 12/12/2025 as payment of his salary in stock, in lieu of cash, at his request and with Compensation Committee approval. The shares were valued at $3.79, the closing price of Agenus common stock on December 12, 2025, and are fully vested on the date of issuance under the company’s 2019 Equity Incentive plan. After this transaction, Dr. Armen directly holds 302,401 Agenus shares, in addition to indirect holdings through IRA accounts and a trust and partnership structure.
Agenus Inc. (AGEN) reported that Chairman and CEO Garo H. Armen received part of his compensation in stock instead of cash. On 11/14/2025, he was issued 3,769 shares of common stock as salary for the pay period ending that date, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. The shares were valued using the $4.34 closing price of Agenus common stock on 11/14/2025 and are fully vested on the date of issuance. Following this transaction, Dr. Armen beneficially owns 294,498 shares directly, with additional indirect holdings reported through IRA accounts and entities in which he has a pecuniary interest.
Agenus Inc. reported Q3 2025 results. Total revenues were $30.2 million, driven mainly by non-cash royalty revenue. The company posted an operating loss of $4.5 million, but recorded a $100.9 million gain from the deconsolidation of MiNK Therapeutics, leading to net income of $63.9 million for the quarter.
On the balance sheet, cash and cash equivalents were $3.5 million as of September 30, 2025. The principal amount of outstanding debt was $35.6 million, and the liability related to the sale of future royalties and milestones was $295.2 million as of September 30, 2025. Shares outstanding were 34,008,349 as of November 7, 2025.
Management disclosed that, despite post-quarter cash actions—including a $10.0 million Zydus promissory note and $4.5 million raised via at-the-market sales—and anticipated $91.0 million from Zydus Lifesciences agreements in Q1 2026, substantial doubt continues to exist about the company’s ability to continue as a going concern for one year after filing. The quarter also reflects the shift to accounting for MiNK under the equity method (fair value option).
Agenus Inc. reported its quarterly results for the period ended September 30, 2025 and furnished the accompanying press release as Exhibit 99.1. The company submitted this information under Item 2.02 of Form 8-K.
The disclosure is designated as “furnished,” not “filed,” meaning it is not subject to Section 18 liabilities and is only incorporated by reference if expressly stated. Agenus’s common stock trades on the Nasdaq Global Market under the symbol AGEN.
Agenus Inc. (AGEN) reported an insider transaction: Chairman and CEO Garo H. Armen acquired 4,120 shares of common stock on 10/31/2025 at $3.97 per share. The shares were issued as salary paid in stock, fully vested upon issuance, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan.
After the transaction, Dr. Armen’s direct beneficial ownership was 290,729 shares. He also holds 31,298 shares indirectly through IRA accounts and 28,950 shares indirectly via a GRAT and a partnership, as noted in the filing.